Xpert test for TB could help prevent deaths in southern Africa, but at substantial cost

November 20, 2012

A rapid test for tuberculosis (TB) could help to reduce TB deaths, improve TB treatment, and also offer reasonably good value for money if introduced in southern Africa, an area that has high rates of HIV and a type of TB that is resistant to some drugs (multi-drug resistant TB), according to a study published in this week's PLOS Medicine.

The World Health Organization (WHO) recently recommended the use of a new diagnostic test for TB (the Xpert MTB/RIF test), which can show a result within 2 hours, in people at high risk of multi-drug resistant TB and/or HIV-associated TB--two increasingly common conditions in many countries.

In a modelling study led by Nicolas Menzies from the Harvard School of Public Health in Boston USA, the authors investigated the potential health and economic consequences of implementing the Xpert test in Botswana, Lesotho, Namibia, South Africa, and Swaziland.

When compared to the current most commonly used testing approach (based on a sputum sample), the authors found that using Xpert instead would prevent an estimated 132,000 TB cases and 182,000 TB deaths in southern Africa over 10 years, reducing by 28% the proportion of the population with active TB.

The authors calculated that health service costs would consequently increase by US$460 million, with much of this extra cost due to increased costs for anti-HIV drugs (antiretroviral therapy) for people with TB-HIV co-infection who would now survive TB infection as a result of improved testing and treatment.

The authors also calculated that using Xpert in southern Africa would cost US$959 for every year of healthy life gained, ranging from US$792 in Swaziland to US$1257 in Botswana--levels which according to WHO standards, are considered cost effective. While these results suggest that scaling up Xpert can be a good health investment, the cost per healthy year gained is substantially higher in this study than in previous reports, and the economic results raise questions about affordability that will be critical for policy makers to consider.

The authors say: "Introduction of Xpert could substantially change TB morbidity and mortality through improved case-finding and treatment."

They continue: "Adoption of Xpert evidently offers reasonable value for its cost, based on conventional benchmarks for cost-effectiveness. However, the additional financial burden would be substantial, including significant increases in costs for treating HIV and multi-drug resistant-TB. "

The authors add: "Given the fundamental influence of HIV on TB dynamics and intervention costs, care should be taken when interpreting the results of this analysis outside of settings with high HIV prevalence."
-end-
Funding: NAM and JAS were supported in part by funding from UNITAID. NAM was also supported by a training grant from the Massachusetts General Hospital's Program in Cancer Outcomes and Training (NIH Grant No. R25 CA092203). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: JAS and MM are members of the PLOS Medicine editorial board. The authors declare that no other competing interests exist.

Citation: Menzies NA, Cohen T, Lin H-H, Murray M, Salomon JA (2012) Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLoS Med 9(11): e1001347. doi:10.1371/journal.pmed.1001347

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER (THIS LINK WILL BECOME LIVE WHEN THE EMBARGO LIFTS):

http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001347

CONTACT:Nicolas A. Menzies
Center for Health Decision Sciences, Harvard School of Public Health, Boston Massachusetts, United States of America


PLOS

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.